Who
Carlos Alban
Director
Company insider
Files Form 4 as: Director, Solventum; Director, SpringWorks Therapeutics; Vice Chairman, AbbVie; Senior Vice President, Abbott Laboratories.
In numbers
- Trades disclosed
- 173
- Buys
- 0
- Sells
- 24
- Bought
- $0
- Sold
- $46.3M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 15 Oct 2009
- Last trade
- 15 May 2026
- Last filed
- 18 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 May 2026filed 18 May 2026 | SOLV Solventumoption or derivative · Medical Devices | SEC FORM 4 Code A | —3,300 at $0.00 | filing |
| 15 May 2026filed 18 May 2026 | SOLV Solventumoption or derivative · Medical Devices | SEC FORM 4 Code A | —3,300 at $0.00 | filing |
| 30 Apr 2026filed 1 May 2026 | SOLV SolventumMedical Devices | SEC FORM 4 Code M | —3,403 at $0.00 | filing |
| 30 Apr 2026filed 1 May 2026 | SOLV Solventumoption or derivative · Medical Devices | SEC FORM 4 Code M | —3,403 at $0.00 | filing |
| 30 Apr 2026filed 1 May 2026 | SOLV Solventumoption or derivative · Medical Devices | SEC FORM 4 Code M | —3,403 at $0.00 | filing |
| 30 Apr 2026filed 1 May 2026 | SOLV SolventumMedical Devices | SEC FORM 4 Code M | —3,403 at $0.00 | filing |
| 27 Mar 2026filed 30 Mar 2026 | SOLV SolventumMedical Devices | SEC FORM 4 Code M | —1,980 at $0.00 | filing |
| 27 Mar 2026filed 30 Mar 2026 | SOLV Solventumoption or derivative · Medical Devices | SEC FORM 4 Code M | —1,980 at $0.00 | filing |
| 27 Mar 2026filed 30 Mar 2026 | SOLV Solventumoption or derivative · Medical Devices | SEC FORM 4 Code M | —1,980 at $0.00 | filing |
| 27 Mar 2026filed 30 Mar 2026 | SOLV SolventumMedical Devices | SEC FORM 4 Code M | —1,980 at $0.00 | filing |
| 1 Jul 2025filed 2 Jul 2025 | SpringWorks Therapeuticsoption or derivative | SEC FORM 4 Code D | —30,160 | filing |
| 1 Jul 2025filed 2 Jul 2025 | SpringWorks Therapeuticsoption or derivative | SEC FORM 4 Code D | —13,774 | filing |
| 1 Jul 2025filed 2 Jul 2025 | SpringWorks Therapeuticsoption or derivative | SEC FORM 4 Code D | —12,216 | filing |
| 1 Jul 2025filed 2 Jul 2025 | SpringWorks Therapeutics | SEC FORM 4 Code D | —28,861 | filing |
| 14 May 2025filed 15 May 2025 | SpringWorks Therapeutics | SEC FORM 4 Code A | —10,060 at $0.00 | filing |
| 13 May 2025filed 15 May 2025 | SOLV Solventumoption or derivative · Medical Devices | SEC FORM 4 Code M | —3,564 at $0.00 | filing |
| 13 May 2025filed 15 May 2025 | SOLV SolventumMedical Devices | SEC FORM 4 Code M | —3,564 at $0.00 | filing |
| 30 Apr 2025filed 2 May 2025 | SOLV Solventumoption or derivative · Medical Devices | SEC FORM 4 Code A | —3,403 at $0.00 | filing |
| 16 May 2024filed 17 May 2024 | SpringWorks Therapeuticsoption or derivative | SEC FORM 4 Code A | —12,216 at $0.00 | filing |
| 16 May 2024filed 17 May 2024 | SpringWorks Therapeutics | SEC FORM 4 Code A | —4,095 at $0.00 | filing |
News
AbbVie vs. Bristol Myers: Is AbbVie's Valuation Premium Worth Paying?ABBV · insidermonkey.com · 19 Oct 2026AbbVie: SKYRIZI (risankizumab) and RINVOQ (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026ABBV · finanznachrichten.de · 17 Oct 2026Pfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment?ABBV · insidermonkey.com · 16 Oct 2026Abbott Laboratories (NYSE:ABT) Given "Buy" Rating at TD CowenABT · dailypolitical.com · 16 Oct 2026Abbott Laboratories is More than a Dividend Stock. Here's Why.ABT · insidermonkey.com · 11 Oct 2026Barclays Initiates Coverage on Abbott Laboratories (NYSE:ABT)ABT · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Carlos Alban; 6 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.